Pomalidomide

For research use only. Not for use in humans.

製品コードS1567 別名:CC-4047

Pomalidomide化学構造

CAS No. 19171-19-8

Pomalidomide (CC-4047) inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 17100
JPY 13600
JPY 21900
JPY 63400
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(69)

製品安全説明書

E3 ligase Ligand阻害剤の選択性比較

生物活性

製品説明 Pomalidomide (CC-4047) inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.
特性 A derivative of thalidomide and up to 10,000 times more potent than thalidomide.
ターゲット
CRBN [5]
()
TNF-α [1]
(PBMCs)
13 nM
体外試験

Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. [1] Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. [2] Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. [3] Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLP-8 NGS4SWtEgXSxdH;4bYNqfHliQYPzZZk> MUixNEDPxE1? NUD0fnJmOjRiaB?= M2DVUZBwfGWwdHz5JIF2\22nboTzJIRqemWldDDhcoQhcW6maYLlZ5QhVU1iY3XscEBscWyuaX7nJIJ6KFODUh?= NWDCPWxXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zN|gzPzNpPkK2N|M5Ojd|PD;hQi=>
J-CD38 MWLDfZRwfG:6aXPpeJkhSXO|YYm= M1rYO|ExKM7:TR?= MXKyOEBp NY\6NI5beG:2ZX70cJkh[XWpbXXueJMh\Gm{ZXP0JIFv\CCrbnTpdoVkfCCPTTDj[YxtKGurbHzpcoch[nliU1HS NFLWSlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOzPFI4Oyd-Mk[zN|gzPzN:L3G+
R-CD38 MVnDfZRwfG:6aXPpeJkhSXO|YYm= NIK4UVUyOCEQvF2= M{fnRVI1KGh? M3nwdpBwfGWwdHz5JIF2\22nboTzJIRqemWldDDhcoQhcW6maYLlZ5QhVU1iY3XscEBscWyuaX7nJIJ6KFODUh?= M3e3bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{O4Nlc{Lz5{NkOzPFI4OzxxYU6=
BC-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPRN|kuOTJ3MDDuUS=> MXG1JIQ> NFPyOYZFVVORwrC= MmK2TWM2OD1zMEegcm0tKGmwaHnibZR{KGOnbHygTWM2OD1zMEegcm0tKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NX7MeIo2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
BCBL-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3iXYRNOzlvMUK1NEBvVQ>? M3XhbVUh\A>? NFX6TJVFVVORwrC= MnT6TWM2OD15NDDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= Mkm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUm5N|koRjJ4MUG5PVM6RC:jPh?=
JSC-1 NEDiNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXSbZgxOzlvMUK1NEBvVQ>? M3fSV|Uh\A>? MULEUXNQyqB? NGrldYxKSzVyPUO0JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 NVm2OHhjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
VG-1 M{fPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy4N2xGOzlvMUK1NEBvVQ>? NIPIO3k2KGR? MlrvSG1UV8Li M2HocmlEPTB;MUCxJI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 M2\DclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
UMPEL-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;VXoNVOzlvMUK1NEBvVQ>? MlrIOUBl NXraUYVjTE2VT9Mg NEnu[4VKSzVyPUOyJI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
UMPEL-3 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17qOlM6NTF{NUCgcm0> NWTkSXYzPSCm MUfEUXNQyqB? MX3JR|UxRTFzMTDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M{\MZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
BC-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYezPU0yOjVyIH7N MV21JIQ> M3TlSmROW00EoB?= NX\2VJdRUUN3ME23OFQhdk1uIHnubIljcXS|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
BCP-1 NWXMRZdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PPOlM6NTF{NUCgcm0> MYK1JIQ> MVLEUXNQyqB? NH61OJdKSzVyPUO5OkBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
APK-1 M1W3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;BO2o{QS1zMkWwJI5O MWe1JIQ> MVTEUXNQyqB? MVPJR|UxRTJ{NjDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NVT1RXpMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
RPMI8226  NEnme4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlGyNE4xOS13MDFOwG0> MXK0PEBp M4jWWmROW00EoB?= MV;JR|UxRThizszN Ml\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOUe4O|IoRjJ4MEm3PFczRC:jPh?=
OPM2  MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLze4NYOC5yMT21NEDPxE1? NXrQRWhxPDhiaB?= MoDGSG1UV8Li MmPwTWM2OD1zMDFOwG0> NV7OOpJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVc5PzJpPkK2NFk4QDd{PD;hQi=>
RPMI8226  NIfvOmFHfW6ldHnvckBCe3OjeR?= NHPhTokyOCEQvF2= NYCwSo5[PDhiaB?= MYHEUXNQyqB? NVzDR4sze3S{ZX7neIhmdnNiY4n0c5Bt[XOvaXOtcpVkdGWjcjDzbJV1fGyrbnegc4YhdVSRUjDhcoQheC2vVF;SJJBzd3SnaX6= NFW0[IU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC5O|g4Oid-Mk[wPVc5PzJ:L3G+
OPM2  M3PEXGZ2dmO2aX;uJGF{e2G7 NVL5fpFzOTBizszN MV:0PEBp MWLEUXNQyqB? M1vuWZN1emWwZ4To[Y5{KGO7dH;wcIF{dWmlLX71Z4xm[XJic3j1eJRtcW6pIH;mJI1VV1JiYX7kJJAudVSRUjDwdo91\Wmw NIq2cog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC5O|g4Oid-Mk[wPVc5PzJ:L3G+
RPMI8226 MYjGeY5kfGmxbjDBd5NigQ>? NWrmU4VGOC5zLUGwJO69VQ>? M4X1U|QhcA>? NFK1[HlFVVORwrC= NXzad2NucW6lcnXhd4V{KF[HR1[gcXJPSSCneIDy[ZN{cW:w MlnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUO5PVAoRjJ3MEWzPVkxRC:jPh?=
SH-SY5Y  NXy0XJVWSXCxcITvd4l{KEG|c3H5 NVXjXIpLOjYEoN88[{9uVA>? NY\yfWFqOcLiaB?= MVnjZZV{\XNic4TheIl{fGmlYXzsfUB{cWewaX\pZ4FvfCC{ZXT1Z5Rqd25iaX6gZo91cCCFUF[tJIFv\CCFUF[rR20ucW6mdXPl[EBieG:ydH;zbZPDqA>? NHviNYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm3OVI4Pid-MkS5O|UzPzZ:L3G+
JJN3 M3;VXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLsUm4xNjFvMUCwJO69VQ>? MVq3NkBp MXPEUXNQ M2OyeYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 NH7mcFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G3PFM4QCd-MkOxO|g{Pzh:L3G+
XG-1 NUO4S3FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofINE4yNTFyMDFOwG0> MVW3NkBp NVrt[ppCTE2VTx?= NIjYdmlqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NHLjR3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G3PFM4QCd-MkOxO|g{Pzh:L3G+
CD138+  NIq5[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC1NE4yNTFyMDFOwG0> NG\K[I44OiCq NXP3Z5V5TE2VTx?= NUfsXW5ucW6qaXLpeJMh[2WubDDndo94fGh? M17ZW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUe4N|c5Lz5{M{G3PFM4QDxxYU6=
XG-1 MXHGeY5kfGmxbjDBd5NigQ>? NYjuc45rOi9zMECg{txO MXiyOEBp NFe4W25FVVOR MonqbY5pcWKrdIOgR2NNOy:PSWCtNe6yKG2UTlGg[ZhxemW|c3nvci=> NYrDU3JVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxO|g{PzhpPkKzNVc5Ozd6PD;hQi=>
U266 M2PEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSwMlAyNTFyIN88US=> NX\wUlcyPDkkgJno M3qwb2ROW09? NFW0Z4pqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV3MkCwPEc,OjJ3NUKwNFg9N2F-
CRBN60 NUfUU2FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjMTFcxNjBzLUGwJO69VQ>? MVu0PQKBkWh? NIrC[Y5FVVOR MUjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NFTOPGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW1NlAxQCd-MkK1OVIxODh:L3G+
CRNB75 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHINE4xOS1zMDFOwG0> NYrYZVZFPDkkgJno M4LvVWROW09? NYXTeY1PcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M{ToPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUWyNFA5Lz5{MkW1NlAxQDxxYU6=
MM.1S M3ywPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\PNE4xOS1zMDFOwG0> MoK5OFjjiImq Mo\HSG1UVw>? Mlnmd4lodmmoaXPhcpRtgSCrbnjpZol1eyCycn;sbYZmemG2aX;uJIF1KGOxbnPlcpRz[XSrb37zJIF{KGyxdzDhd{AxNjBzzszN NIfufJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO4PVMzPyd-MkGzPFk{Ojd:L3G+
OPM2 NW[2VZpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L2[lAvODFvMUCg{txO MoGzOFjjiImq NEP4epJFVVOR M3XR[pNq\26rZnnjZY51dHliaX7obYJqfHNicILvcIln\XKjdHnvckBifCClb37j[Y51emG2aX;ud{BieyCub4egZZMhOC5yMd88US=> Ml;WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OEmzNlcoRjJzM{i5N|I4RC:jPh?=
MM.1S M37sTWZ2dmO2aX;uJGF{e2G7 NXvsUGVsOTBizszN MnLnO|IhcA>? NETybIVFVVOR NFLWVFd{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUheHKxdHXpckBt\X[nbDDv[kBEN0WEUN8yJIl{d2[xcn3zxsA> NYjWUmljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzPFk{OjdpPkKxN|g6OzJ5PD;hQi=>
H929 M4myNWZ2dmO2aX;uJGF{e2G7 NIW3NmwyOCEQvF2= NFHDT|E4OiCq NGDiO3NFVVOR M{TOR5Nq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBxem:2ZXnuJIxmfmWuIH;mJGMwTUKSzsKgbZNw\m:{bYRCpC=> M2fIVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
OPM2 NH\Z[ZZHfW6ldHnvckBCe3OjeR?= MkjYNVAh|ryP MmHQO|IhcA>? NVe0ZYY4TE2VTx?= NYL1SlJPe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXygc4YhSy:HQmFOtkBqe2:ob4Ltd:Kh Moi4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OEmzNlcoRjJzM{i5N|I4RC:jPh?=
CT26 NXTNUWZsTnWwY4Tpc44hSXO|YYm= MkLuNU8yOCEQvF2= MYCyOEBp NWnkT29{emWmdXPld{B1cGViboXtZoVzeyCxZjDsbZZmKGOxbH;ubYV{yqB? Mne1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4M{i5O|coRjF7NkO4PVc4RC:jPh?=
T-cells NFu1Vm9HfW6ldHnvckBie3OjeR?= NGLnU20zKHSxIEOg[IF6ew>? NYfOUFhmUW6qaXLpeIlwdiCxZjDJUE0zKHC{b3T1Z5Rqd25iaX6gbJVu[W5iVDDj[YxteyCvZXHzeZJm\CCjZoTldkAzKHSxIEOg[IF6eyCkeTDFUGlUSSxiRVO1NEA:KDBwMEC4JO69VS5? NHTtflY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G2PFAyQSd-MkOxOlgxOTl:L3G+
DF15 NEHMfXBHfW6ldHnvckBie3OjeR?= MY[0JIhzew>? M3PGe2lv\HWldHnvckBw\iClZYLlZoxwdi2vZXTpZZRm\CCjaX;sc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iRF[xOUBk\WyuczDlfJBz\XO|aX7nJIVRVC22YXfn[YQh[WmxbH;zJIFnfGW{IESgbJJ{KGK7IHz1cYlvd22ndILpZ{BidmGueYPpd{whTUN3MDC9JFAvODJ{IN88UU4> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{NUeyNEc,Ojh2MkW3NlA9N2F-
DF15 MX\GeY5kfGmxbjDhd5NigQ>? NIX2T281KGi{cx?= M37Xfmlv\HWldHnvckBw\iClZYLlZoxwdi2vZXTpZZRm\CCra3Hyc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iRF[xOUBk\WyuczDlfJBz\XO|aX7nJIVRVC22YXfn[YQhcWujcn;zJIFnfGW{IESgbJJ{KGK7IHz1cYlvd22ndILpZ{BidmGueYPpd{whTUN3MDC9JFAvODJ2IN88UU4> M{Lpc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=
DF15 MnHtSpVv[3Srb36gZZN{[Xl? MlPxOEBpenN? NULOVpBDUW6mdXP0bY9vKG:oIFPSUFQwS1KETjD1ZolyfWm2aX6gcIlo[XOnLX3l[IlifGWmIHHpc4xweyCmZXfyZYRifGmxbjDpckBpfW2jbjDESlE2KGOnbHzzJIV5eHKnc4PpcocheEyRQz3lVGwufGGpZ3XkJIFqd2yxczDh[pRmeiB2IHjyd{BjgSCudX3pcoV{[2WwY3WgZoF{\WRiYnX0ZU1o[WyjY4Tvd4ll[XOnIHXufplu\SCocnHncYVvfGG2aX;uJINwdXCuZX3lcpRifGmxbjDhd5NigSxiRVO1NEA:KDBwMEK3JO69VS5? NHjPZZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO1PFUxPyd-MkizOVg2ODd:L3G+
NAMALWA MlvaRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NFHZUpY4OiCqcoO= MkD3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQV3BUHdCKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gX|NJZXSqeX3p[Ilv\SCrbnPvdpBwemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCLQ{WwJF0hOC5yMzFOwG0v MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF4OECxPUc,OjNzNkiwNVk9N2F-
HeLa MoP4SpVv[3Srb36gZZN{[Xl? NE\lXlJKdmirYnn0bY9vKG:oIFnMMVEu[WyyaHGtbY5lfWOnZDDOSk1s[XCyYVKgZYN1cX[jdHnvckBqdiCKZVzhJINmdGy|IHHzd4V{e2WmIHHzJIJtd2OtaX7nJI9nKHB3MD;wOlUhdnWlbHXhdkB1emGwc3zvZ4F1cW:wLDDJR|UxKD1iMT6yO{DPxE1w MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzh2NUi1NEc,OTd6NEW4OVA9N2F-
DF15 NHrWVGFHfW6ldHnvckBie3OjeR?= NWXm[IVVOC5yMTD0c{AyKHWP MW[1JIhzew>? M1TlS2lv\HWldHnvckBw\iClZYLlZoxwdi2vZXTpZZRm\CCjaX;sc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iRF[xOUBk\WyuczDheEAxNjBzIITvJFEhfU1iYX\0[ZIhPSCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? NFm3fJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOVczOCd-Mki0NlU4OjB:L3G+
OPM2 M1y5S2Z2dmO2aX;uJIF{e2G7 NWHXbXZoOC5yMTD0c{AyKHWP MXi1JIhzew>? MYjJcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQhcWujcn;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKE:STUKgZ4VtdHNiYYSgNE4xOSC2bzCxJJVOKGGodHXyJFUhcHK|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{NUeyNEc,Ojh2MkW3NlA9N2F-
DF15 M3zVV2Z2dmO2aX;uJIF{e2G7 MWSwMlAyKHSxIEGgeW0> MVW1JIhzew>? NFLadnVKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiaXvhdo9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOgZZQhOC5yMTD0c{AyKHWPIHHmeIVzKDViaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? NVm3N3c2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
OPM2 NGXJPVdHfW6ldHnvckBie3OjeR?= Mmm4NE4xOSC2bzCxJJVO NFvwZWU2KGi{cx?= NYHwUIRXUW6mdXP0bY9vKG:oIHPldoVjdG:wLX3l[IlifGWmIHHpc4xweyCmZXfyZYRifGmxbjDpckBpfW2jbjDPVG0zKGOnbHzzJIF1KDBwMEGgeI8hOSC3TTDh[pRmeiB3IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m| MoHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MkW3NlAoRjJ6NEK1O|IxRC:jPh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
CEBPβ; 

PubMed: 21389327     


MM.1S, H929, OPM2, or primary myeloma cells were cultured with DMSO, pomalidomide, or lenalidomide at the indicated concentrations for 3 days. Representative results from 3 independent experiments are shown. Cells were then lysed, and cell lysates were an䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ

IKZF1 / IKZF3 / UBE2G1 / CRBN ; 

PubMed: 30234487     


Immunoblot analysis of SKMM2 cells transduced with lentiviral vectors encoding GFP, UBE2G1 and UBE2G1-C90S. Cells were treated with DMSO vehicle control, LEN or POM at the indicated concentrations for 16 hr.

21389327 30234487
Immunofluorescence
IKZF1; 

PubMed: 29496670     


CD34+ cells were treated with DMSO (0.01%), LEN, or POM (1 μM) for 6 hours. The cells were then fixed and stained for IKZF1 (red color), and nuclear counterstaining was performed with DAPI (blue color). The localization of IKZF1 was observed using a Leica䲧疝Ỵ疞㧀疜膉痘 

29496670
体内試験

Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

- 合併

Inhibition of TNF-α synthesis:

TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.
細胞試験:

[4]

- 合併
  • 細胞株: Raji, SU-DHL-4 and SU-DHL-10 cell lines
  • 濃度: Dissolved in DMSO, final concentrations 2.5-40 μg/mL
  • 反応時間: 24 or 48 hours
  • 実験の流れ:

    For assessment of cell apoptosis, Lymphoma cell lines are exposed to Pomalidomide (5 μg/mL) for 24 hours or 48 hours. The cells are stained with FITC-labeled Annexin V and propidium iodine. Cell apoptosis is analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells are scored as apoptotic if they are Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively). For determination of cell proliferation, the Lymphoma cell lines are exposed to Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL) for 24 hours or 48 hours. 1 μCi per well (96-well plate) of [3H]-thymidine is added and cells are incubated for another 18 hours. Cells are then harvested using the Harvest system into the 96-well glass filters and [3H]-thymidine uptake is measured using an automated scintillation counter.


    (参考用のみ)
動物試験:

[4]

- 合併
  • 動物モデル: Disseminated lymphoma-bearing SCID mice
  • 投薬量: 0.5 mg/kg
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 54 mg/mL (197.62 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 273.24
化学式

C13H11N3O4

CAS No. 19171-19-8
Storage powder
in solvent
別名 CC-4047
Smiles C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04191616 Recruiting Drug: Carfilzomib|Drug: Dexamethasone|Drug: Pomalidomide Relapsed or Refractory Multiple Myeloma Amgen August 6 2020 Phase 2
NCT04305444 Recruiting Drug: DTRM-555 Relapsed Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Richter''s Transformation Zhejiang DTRM Biopharma April 24 2020 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1567 in the 1% DMSO+30% polyethylene glycol+1% Tween 80 suitable for oral administration?

  • 回答:

    S1567 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension. This formulation is for oral gavege.

  • 質問2:

    I would like to know if the pomalidomide is racemic or optically active?

  • 回答:

    Our S1567 Pomalidomide is racemic.

E3 ligase Ligand Inhibitors with Unique Features

Tags: Pomalidomideを買う | Pomalidomide ic50 | Pomalidomide供給者 | Pomalidomideを購入する | Pomalidomide費用 | Pomalidomide生産者 | オーダーPomalidomide | Pomalidomide化学構造 | Pomalidomide分子量 | Pomalidomide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID